company background image
INVA

Innoviva NasdaqGS:INVA Stock Report

Last Price

US$14.76

Market Cap

US$925.4m

7D

6.6%

1Y

8.2%

Updated

07 Dec, 2023

Data

Company Financials +

INVA Stock Overview

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally.

INVA fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Innoviva, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Innoviva
Historical stock prices
Current Share PriceUS$14.76
52 Week HighUS$14.78
52 Week LowUS$10.64
Beta0.52
1 Month Change7.82%
3 Month Change16.96%
1 Year Change8.21%
3 Year Change42.47%
5 Year Change-14.29%
Change since IPO-18.50%

Recent News & Updates

Is Innoviva (NASDAQ:INVA) A Risky Investment?

Nov 04
Is Innoviva (NASDAQ:INVA) A Risky Investment?

Recent updates

Is Innoviva (NASDAQ:INVA) A Risky Investment?

Nov 04
Is Innoviva (NASDAQ:INVA) A Risky Investment?

Innoviva (NASDAQ:INVA) Seems To Use Debt Quite Sensibly

Mar 02
Innoviva (NASDAQ:INVA) Seems To Use Debt Quite Sensibly

Innoviva Stock? Not Yet. Short Puts? Definitely.

Sep 19

Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Sep 19
Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Jun 16
Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Continuing To Avoid Innoviva Inc.

Jun 07

We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease

Mar 04
We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease

Taking Innoviva Winnings Off The Table, Again

Feb 21

Innoviva Inc.: Short Puts Are Compelling

Jan 15

Is Innoviva (NASDAQ:INVA) A Risky Investment?

Oct 19
Is Innoviva (NASDAQ:INVA) A Risky Investment?

Taking Profits In Innoviva Inc.

Oct 16

Innoviva reports Q1 results

Apr 28

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Mar 30
These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Mar 04
Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?

Jan 15
Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Dec 25
These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?

Dec 04
Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?

Innoviva: Only For Short-Term Traders

Nov 04

Innoviva reports Q3 results

Oct 28

Shareholder Returns

INVAUS PharmaceuticalsUS Market
7D6.6%0.1%0.5%
1Y8.2%-4.0%14.4%

Return vs Industry: INVA exceeded the US Pharmaceuticals industry which returned -2.6% over the past year.

Return vs Market: INVA underperformed the US Market which returned 14.7% over the past year.

Price Volatility

Is INVA's price volatile compared to industry and market?
INVA volatility
INVA Average Weekly Movement3.5%
Pharmaceuticals Industry Average Movement10.9%
Market Average Movement6.1%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.9%

Stable Share Price: INVA is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: INVA's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996101Pavel Raifeldhttps://www.inva.com

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP.

Innoviva, Inc. Fundamentals Summary

How do Innoviva's earnings and revenue compare to its market cap?
INVA fundamental statistics
Market CapUS$925.41m
Earnings (TTM)US$49.88m
Revenue (TTM)US$290.43m

19.0x

P/E Ratio

3.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
INVA income statement (TTM)
RevenueUS$290.43m
Cost of RevenueUS$64.74m
Gross ProfitUS$225.69m
Other ExpensesUS$175.81m
EarningsUS$49.88m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.78
Gross Margin77.71%
Net Profit Margin17.17%
Debt/Equity Ratio71.0%

How did INVA perform over the long term?

See historical performance and comparison